Welcome to our dedicated page for Sera Prognostics SEC filings (Ticker: SERA), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Sera Prognostics, Inc. filings document a public women's health diagnostics company focused on pregnancy biomarker information and the PreTRM® Test. Recent 8-K reports furnish quarterly and annual financial results, business highlights, investor presentations and Regulation FD disclosures tied to PRIME study publications and PreTRM clinical evidence.
Its proxy materials describe annual meeting matters, corporate governance, shareholder voting items, strategic priorities, capital allocation and commercial progress. The filing record also covers securities-law treatment of furnished press releases and exhibits related to results, clinical data and market-adoption updates.
Sera Prognostics, Inc. furnished an 8‑K announcing financial results for the third quarter ended September 30, 2025. The company disclosed the results and business highlights via a press release furnished as Exhibit 99.1.
The information under Item 2.02, including Exhibit 99.1, is furnished and not deemed “filed” under Section 18 of the Exchange Act, and is not incorporated by reference except as expressly stated.
Sera Prognostics (SERA) reported an insider transaction by its Chief Executive Officer and Director. On 11/10/2025, the reporting person sold 11,594 shares of Class A common stock at a weighted average price of $2.62. The filing states the sale was executed to cover tax withholding obligations tied to the vesting of RSUs and was not a discretionary trade. The shares were sold via a block trade within a price range of $2.30–$3.04. Following the transaction, the insider beneficially owns 796,296 shares.
Sera Prognostics (SERA) insider transaction: the company’s Chief Data Officer reported a sell-to-cover trade tied to RSU vesting. On 11/10/2025, 7,073 shares of Class A common stock were sold to satisfy tax withholding, a non-discretionary transaction under the issuer’s “sell to cover” election.
The sale executed at a $2.62 weighted average price within a $2.30–$2.62 range. Following the transaction, the reporting person beneficially owns 168,596 shares, held directly.
Sera Prognostics (SERA): Form 4 insider transaction. The company’s General Counsel reported the sale of 7,059 shares of Class A common stock on 11/10/2025 at a weighted average price of $2.62. The filing states the shares were sold to satisfy tax withholding obligations tied to RSU vesting under a mandated “sell to cover,” indicating it was not a discretionary trade. Following the transaction, the insider directly beneficially owns 119,758 shares. The sale was executed as a block trade with prices ranging from $2.30 to $3.04.
Sera Prognostics (SERA) reported an insider transaction by its Chief Information Officer. On 11/10/2025, the officer sold 6,528 Class A common shares in a mandated “sell to cover” to satisfy tax withholding triggered by RSU vesting. The transaction is noted as non‑discretionary under the company’s election.
The shares were sold at a weighted average price of $2.62, with individual trades ranging from $2.30 to $3.04. Following the transaction, the reporting person beneficially owns 89,404 shares, held directly.
Sera Prognostics (SERA) insider transaction: the company’s Chief Scientific Officer reported a sale of 7,767 shares of Class A common stock on 11/10/2025 at a weighted average price of $2.62. The filing states the sale was made to cover tax withholding upon RSU vesting under a mandated “sell to cover” arrangement.
Following the transaction, the reporting person beneficially owned 151,726 shares, held directly. The block trade occurred across prices ranging from $2.30 to $3.04.
Sera Prognostics (SERA) disclosed an insider transaction by its Chief Financial Officer. On 11/10/2025, the officer sold 6,351 shares of Class A common stock at a weighted average price of $2.62 to cover tax withholding tied to RSU vesting, as required by the issuer’s sell-to-cover policy. The block trade occurred across multiple transactions priced between $2.30 and $3.04. After the sale, the officer beneficially owns 278,319 shares, held directly.
Sera Prognostics (SERA) filed a Form 4 reporting a routine sell-to-cover. On 11/05/2025, a director sold 221 shares of Class A common stock at a $3.04 weighted average price to satisfy tax withholding from vested RSUs. The filing notes the sale was mandated by the issuer’s “sell to cover” election and was not a discretionary trade by the insider. Following the transaction, the reporting person beneficially owns 58,032 shares, held directly. The shares were sold in multiple trades between $3.03 and $3.05.
Sera Prognostics (SERA) reported a Form 4 for its Chief Information Officer, who sold 2,000 shares of Class A common stock on 11/04/2025 at a weighted average price of $3.07.
The sale was effected under a Rule 10b5-1 trading plan adopted on May 21, 2025, with trade prices ranging from $3.02 to $3.15. Following the transaction, the officer beneficially owns 95,932 shares, held directly.
Sera Prognostics (SERA) filed a Form 4 reporting equity awards to its Chief Medical Officer. On 10/15/2025, the officer acquired 75,000 shares of Class A Common Stock represented by RSUs at a price of $0, bringing beneficial ownership of these shares to 75,000, held directly.
The filing also reports a stock option grant for 107,000 shares at an exercise price of $3.13, expiring on 10/15/2035, with 107,000 derivative securities beneficially owned directly. The RSUs vest over four years: 25% on the first anniversary of the vesting commencement date, which is October 10, 2025, then 1/12 of the remainder in quarterly installments for three years thereafter. The options vest over four years: 25% on the first anniversary of the vesting commencement date, which is October 10, 2025, then 1/36 of the remainder in monthly installments for three years thereafter.